21PClinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients. (24th November 2019)

• Record Type: Journal Article
• Authors: Aye, T T; Mon, S; Khine, M; Sein, N; Thant, N M; Win, A K; Aung, E P P; Hnin, P T
• Is Part Of: Annals of oncology. Volume 30(2019)Supplement 9
• Publication Date: 2019-11-24
• Subjects: Oncology -- Periodicals; 616.992
• DOI: 10.1093/annonc/mdz416.020
• Languages: English
• ISSNs: 0923-7534

Abstract

Abstract: Background: Due to the limited accessibility of trastuzumab, the majority of Her2 positive breast cancer patients are treated mainly with systemic chemotherapy in Myanmar. This study aimed to find out the clinical outcome of treatment without trastuzumab for Her2 positive breast cancer patients. Methods: A retrospective observational study of total 156 Her2 positive breast cancer patients not receiving anti-her2 therapy who diagnosed between January 2007 and December 2016 in two private oncology centers in Yangon, Myanmar. Results: In this study, median age of patients was 52 years (25yrs-87yrs). Majority (80%, n = 126) were in early stage. Regarding treatment pattern, 99% of patients underwent either simple or total mastectomy and only 1% was done breast conserving surgery. Anthracycline containing regimes (AC-T or FAC) were given in 99% of patients. Among them, 26% (n = 40) took additional maintenance chemotherapy with oral cyclophosphamide and methotrexate for 3 to 6 months after conventional chemotherapy. After a median follow up of 40 months (8-120), 80% of patients achieved complete response. The median disease free period was 34 months and 3 year invasive disease free survival was 79%. The relapse rate was 17.3%. Lymph nodes (23%) and liver metastases (23%) were the first site of recurrence in relapsed patients. Furthermore, 92% had no recurrence among those received maintenance chemotherapy. Conclusions: Anthracycline based systemic chemotherapy without anti Her2 therapy showed good clinical outcome in Her2 positive breast cancer patients in real clinical practice in Myanmar. Legal entity responsible for the study: Medical oncology academic group. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.